Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ultomiris (ravulizumab-cwvz)
Pharma
Argenx's Vyvgart holds its own against AZ's rare disease duo
For 2024’s second quarter, infused Vyvgart and its subcutaneous sibling Vyvgart Hytrulo brought home $478 million in sales.
Fraiser Kansteiner
Jul 25, 2024 3:16pm
AstraZeneca's rare disease add-on therapy Voydeya scores FDA nod
Apr 1, 2024 11:48am
FDA expands AZ's Ultomiris to NMOSD after prior rejection
Mar 25, 2024 10:31am
Roche's answer to AstraZeneca PNH drugs nabs China nod
Feb 8, 2024 11:02am
Novartis gains first FDA approval for touted blood disorder drug
Dec 6, 2023 11:02am
With Zilbrysq, UCB gains its second FDA nod in gMG in 4 months
Oct 18, 2023 1:08pm
